THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS

被引：0
|
作者：
Herter, S. [1 ]
Del Giudice, I. [2 ]
Schmidt, C. [1 ]
Fauti, T. [1 ]
Klein, C. [3 ]
Umana, P. [1 ]
Dyer, M. J. S. [4 ]
Foa, R. [2 ]
Grau, R. [1 ]
机构：
[1] Glycart Biotechnol AG, Schlieren, Switzerland
[2] Univ Roma La Sapienza, Rome, Italy
[3] Roche Diagnost GmbH, Penzberg, Germany
[4] Univ Leicester, Leicester, Leics, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0910
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [1] Unique molecular recognition of CD20 by the type II CD20 antibody GA101
    Niederfellner, G. J.
    Lammens, A.
    Georges, G. J.
    Schwaiger, M.
    Franke, A.
    Wiechmann, K.
    Moessner, E.
    Umana, P.
    Hopfner, K. P.
    Klein, C.
    EJC SUPPLEMENTS, 2010, 8 (07): : 75 - 76
  • [2] GA101 IS A HIGHLY EFFICACIOUS TYPE II ANTI-CD20 MONOCLONAL ANTIBODY THAT INDUCES DIRECT CELL DEATH BUT LOW COMPLEMENT MEDIATED CYTOTOXICITY IN B-CLL WHOLE BLOOD ASSAYS
    Bologna, L.
    Golay, J.
    Gotti, E.
    Rambaldi, A.
    Intermesoli, T.
    Introna, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 184 - 184
  • [3] THE TYPE II CD20 ANTIBODY GA101 DIFFERS FROM THE TYPE I CD20 ANTIBODY RITUXIMAB IN INDUCING DIFFERENTIAL GENE EXPRESSION PROFILES AND BY BINDING SEPARATE AND FUNCTIONALLY DISTINCT CD20 COMPLEXES ON B CELL LYMPHOMA CELL LINES
    Niederfellner, G.
    Mundigl, O.
    Lifke, A.
    Franke, A.
    Baer, U.
    Burtscher, H.
    Belousov, A.
    Maisel, D.
    Umana, P.
    Klein, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 241 - 241
  • [4] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Kensei Tobinai
    Christian Klein
    Naoko Oya
    Günter Fingerle-Rowson
    Advances in Therapy, 2017, 34 : 324 - 356
  • [5] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Tobinai, Kensei
    Klein, Christian
    Oya, Naoko
    Fingerle-Rowson, Gunter
    ADVANCES IN THERAPY, 2017, 34 (02) : 324 - 356
  • [6] Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab
    Herter, Sylvia
    Waldhauer, Inja
    Otz, Tina
    Herting, Frank
    Lang, Sabine
    Nicolini, Valeria
    Roemmele, Michaela
    Friess, Thomas
    Van Puijenbroek, Erwin
    Bacac, Marina
    Weidner, K. Michael
    Gerdes, Christian
    Umana, Pablo
    Klein, Christian
    BLOOD, 2010, 116 (21) : 1601 - 1601
  • [7] ENHANCED ACTIVITY OF THE TYPE II, GLYCOENGINEERED CD20 ANTIBODY GA101 IN COMBINATION WITH BENDAMUSTINE, FLUDARABINE, AND CHLORAMBUCIL
    Herting, F.
    Umana, P.
    Klein, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 198 - 199
  • [8] Differential Patterns of Gene Expression and CD20 Localisation by the Type II Anti-CD20 Antibody Obinutuzumab (GA101) Compared with the Type I Antibody Rituximab Suggests Binding to Functionally Distinct CD20 Subpopulations on B-Cell Lymphoma Cell Lines
    Niederfellner, Gerhard
    Mundigl, Olaf
    Lifke, Alexander
    Franke, Andreas
    Baer, Ute
    Burtscher, Helmut
    Maisel, Daniela
    Belousov, Anton
    Weidner, K. Michael
    Umana, Pablo
    Klein, Christian
    BLOOD, 2011, 118 (21) : 1589 - 1590
  • [9] Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
    Goede, Valentin
    Klein, Christian
    Stilgenbauer, Stephan
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (04) : 185 - 192
  • [10] Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
    Herter, Sylvia
    Herting, Frank
    Mundigl, Olaf
    Waldhauer, Inja
    Weinzierl, Tina
    Fauti, Tanja
    Muth, Gunter
    Ziegler-Landesberger, Doris
    Van Puijenbroek, Erwin
    Lang, Sabine
    Minh Ngoc Duong
    Reslan, Lina
    Gerdes, Christian A.
    Friess, Thomas
    Baer, Ute
    Burtscher, Helmut
    Weidner, Michael
    Dumontet, Charles
    Umana, Pablo
    Niederfellner, Gerhard
    Bacac, Marina
    Klein, Christian
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) : 2031 - 2042
12345